Group 1 - The company has developed a microbial protein that is efficient, sustainable, and free from antibiotics, featuring high protein, high dietary fiber, low sugar, low fat, and zero cholesterol characteristics [2] - The amino acid composition of the product closely matches human nutritional needs, and it is currently available for sale in major retail stores and online platforms [2] - The company announced that its microbial protein has recently received new food ingredient certification from the National Health Commission, and it is actively negotiating with downstream customers to promote the launch of end-consumer products [2]

Group 1 - Jiangxi Fuxiang Pharmaceutical Co., Ltd. (stock code: 300497) has officially signed a strategic cooperation agreement with the pharmaceutical information and networking platform Yaorongquan, aiming for deep integration in the pharmaceutical and biomanufacturing sectors to promote technological innovation and industrialization [1][13] - The cooperation will focus on Fuxiang's three major industry segments: pharmaceuticals, new energy materials, and biomanufacturing, enhancing collaboration in product development, visual systems, key projects, and talent recommendations [8][20] - Fuxiang has established itself as a significant player in the biomanufacturing field, with its subsidiary Fuxiang Biotechnology being the first in China to achieve ton-level industrialization of new protein, with an annual production line capacity of 1,200 tons [2][15] Group 2 - Fuxiang Pharmaceutical has received approval from the National Health Commission, marking a milestone in its biomanufacturing development and positively impacting domestic food manufacturing and national food security [6][18] - The company operates in three main sectors: pharmaceuticals, new energy materials, and biomanufacturing, with a strong focus on antibiotic raw materials and lithium battery electrolyte additives [9][22] - In the biomanufacturing sector, Fuxiang is recognized as Asia's first company to achieve ton-level industrialization of filamentous fungal protein and has developed a new production strain with independent intellectual property rights, currently holding a national invention patent [10][23]

Core Insights - The National Health Commission of China has approved "Venetian Sclerotium Protein" as a new food ingredient, marking it as the first filamentous fungus-derived microbial protein approved in the country [1] - This approval signifies Jiangxi Province's advancement in the forefront of microbial protein development and represents a milestone for the "2030 Pioneer Project" focused on high-quality microbial protein manufacturing [1][3] Industry Overview - Traditional protein sources heavily rely on livestock farming, which struggles to meet the increasing demand due to population growth and rising living standards, leading to environmental pollution and resource waste [3] - Filamentous fungus-derived microbial protein offers a sustainable alternative with high manufacturing efficiency and lower carbon emissions, contributing to national protein supply security and supporting carbon neutrality goals [3] Company Developments - Jiangxi Fuxiang Pharmaceutical Co., Ltd. has established a pilot production line for microbial protein with a capacity of thousands of tons, and is advancing the construction of a large-scale production line with an expected annual output of 20,000 tons [5] - The projected annual output value after full production is anticipated to exceed 2 billion yuan [5] - The company has completed regulatory submissions for its microbial protein in major international markets, including the US, Singapore, and Europe, establishing a development framework of "Jiangxi R&D, International Standards, Global Promotion" [5] Future Plans - Jiangxi Fuxiang Pharmaceutical aims to accelerate the transformation of its core brand "Weiran Protein" into downstream products such as plant-based meat and protein beverages, creating a complete industrial chain from technological innovation to consumer application [5] - The goal is to foster a biomanufacturing industry cluster worth 10 billion yuan [5]

Group 1: Company Achievements and Certifications - The company’s Wei Ran protein has officially passed the National Health Commission's administrative approval, obtaining new food raw material certification, which serves as a significant milestone in its development [2][3] - The certification allows Wei Ran protein to enter the Chinese food market, establishing a "dual certification" global market framework, enhancing international competitiveness and risk resistance [3] - Wei Ran protein features a nutritional profile of "high protein, high dietary fiber, low fat, and zero cholesterol," meeting modern consumer demands for healthy diets [3] Group 2: Market and Industry Impact - The successful certification provides a replicable model for the approval and commercialization of the fungal protein industry in China, boosting industry confidence and attracting more capital and talent [3] - The development of Wei Ran protein aligns with national strategies for protein supply security and reducing reliance on imported soybeans, contributing to environmental sustainability [4] Group 3: Future Capacity and Business Strategy - The company plans to leverage its technological advantages and circular economy model to maintain industry leadership and expand both domestic and international markets [5] - Future capacity releases will focus on optimizing production processes and raw material costs, enhancing competitive advantages [5] Group 4: Business Performance and Growth Projections - The pharmaceutical manufacturing segment is expected to benefit from a 41% decrease in the price of 6-APA, alongside growing market demand for downstream products [6] - The lithium battery additive business is experiencing rapid price increases due to rising demand from energy storage and power battery sectors [7] - The company’s synthetic biology business has received approval for Wei Ran protein as a new food raw material, facilitating its commercialization and global market entry [7] Group 5: Risk Management and Investor Relations - All information disclosed by the company is based on official announcements, urging investors to make rational investment decisions and be aware of risks [8]

Core Points - The National Health Commission of China has approved the safety assessment of Venetian scythe fungus protein as a new food ingredient, allowing its production and sale domestically, which will accelerate the commercialization of the product by the company [1] - The approval supports national food security and aims to meet the growing demand for high-quality protein in China [1] Company Summary - Fujian Bio has obtained certifications for its Venetian scythe fungus protein from regulatory bodies in China, the United States, Singapore, and Europe, establishing a solid foundation for global commercial application [2] - The protein is high in content, containing 18 essential amino acids, dietary fiber, and minerals such as calcium, zinc, and iron, while ensuring zero antibiotics, pesticide residues, and hormones [2] - The company has developed two product forms: dry and wet, targeting applications in various sectors including plant-based meat, protein beverages, baked goods, dairy alternatives, health foods, special medical foods, and pet foods [2] - Fujian Bio aims to build an internationally competitive full industry chain for the fungus protein, currently having an annual production capacity of 1,200 tons and is accelerating the construction of a project with a capacity of 20,000 tons per year [2] - Upon completion, the project will produce 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer, positioning the company to potentially lead the industry in production capacity [2]

Market Overview - As of November 28, the Shanghai Composite Index closed at 3888.60 points, up 13.34 points, with a gain of 0.34% [1] - The Shenzhen Component Index closed at 12984.08 points, up 108.89 points, with a gain of 0.85% [1] - The ChiNext Index closed at 3052.59 points, up 21.29 points, with a gain of 0.70% [1] Stock Performance - A total of 78 A-shares had a turnover rate exceeding 20% on this day [1] - Notable stocks with high turnover rates include: - Dapeng Industrial (stock code: 920091) with a turnover rate of 42.36% and a closing price of 58.80 CNY, down 2.54% [1] - Haixin Food (stock code: 002702) with a turnover rate of 40.07% and a closing price of 7.24 CNY, up 10.03% [1] - Annie Shares (stock code: 002235) with a turnover rate of 39.66% and a closing price of 9.29 CNY, down 1.38% [1] - Haike Xinyuan (stock code: 301292) with a turnover rate of 39.34% and a closing price of 80.62 CNY, up 7.31% [1] Additional Notable Stocks - Other stocks with significant turnover rates include: - Nante Technology (stock code: 920124) with a turnover rate of 39.15% and a closing price of 20.72 CNY, down 15.46% [1] - New Jinlu (stock code: 000510) with a turnover rate of 39.07% and a closing price of 8.97 CNY, up 5.65% [1] - Aerospace Universe (stock code: 688523) with a turnover rate of 36.68% and a closing price of 38.04 CNY, up 20.00% [1] Summary of Turnover Rates - The data indicates a strong interest in certain stocks, with several companies experiencing significant fluctuations in their stock prices alongside high turnover rates, suggesting active trading and potential volatility in the market [1][2][3]

Core Insights - Jiangxi Fuxiang Pharmaceutical's subsidiary, Fuxiang Biotechnology, has received approval for the safety assessment of Venetian Fusarium protein, marking a significant milestone in the synthetic biology sector and boosting the development of alternative protein industries in China [1][2] Group 1: Product and Market Impact - The approved product, Venetian Fusarium protein (marketed as "Weiran Protein"), is a filamentous fungal protein with high nutritional value, containing 18 essential amino acids, dietary fiber, and minerals such as calcium, zinc, and iron [1] - Weiran Protein is free from antibiotics, pesticide residues, and hormones, ensuring food safety and health for consumers, with applications in various sectors including plant-based meat, protein beverages, baked goods, dairy alternatives, health foods, and pet foods [1][2] Group 2: Environmental Benefits - Weiran Protein production offers significant environmental advantages, reducing water usage and land occupation by over 90% compared to traditional animal protein production, and lowering carbon emissions by 70% to 80% [2] - The production process also generates amino acid water-soluble fertilizers, promoting resource-efficient conversion and zero emissions, thereby maximizing environmental friendliness and enhancing economic benefits [2] Group 3: Company Development and Strategy - Fuxiang Pharmaceutical has transitioned from a pharmaceutical giant to a pioneer in synthetic biology, leveraging over 20 years of experience in the antibiotic raw material sector to establish a leading position in the microbial protein field [3] - The company has achieved an annual production capacity of 1,200 tons of Weiran Protein and is advancing a project aimed at producing 200,000 tons of microbial protein and resource utilization, which will significantly enhance its production scale [3] - The recent certification is a key outcome of the company's "pharmaceutical + new energy + synthetic biology" strategy, aiming to accelerate domestic commercialization and meet the growing demand for high-quality protein while contributing to food security and carbon neutrality goals [3]

江西富祥药业股份有限公司第一期股票期权激励计划（草案）摘要 证券代码：300497 证券简称：富祥药业 江西富祥药业股份有限公司 第一期股票期权激励计划（草案）摘要 生命•阳光•未来 二〇二五年十一月 1 江西富祥药业股份有限公司第一期股票期权激励计划（草案）摘要 声明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2 江西富祥药业股份有限公司第一期股票期权激励计划（草案）摘要 特别提示 一、江西富祥药业股份有限公司（以下简称"公司"）第一期股票期权激励计划 （以下简称"本激励计划"）系依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》等有关法律法 规、规范性文件，以及《公司章程》制订。 二、本激励计划采用的激励工具为股票期权。股票来源为公司向激励对象定向 发行的公司A股普通股股票。 三、本激励计划拟向激励对象授予不超过620万份的股票期权，约占本激励计划 草案公告时公司股本总额的1.15% ...

江西富祥药业股份有限公司 第一期股票期权激励计划首次授予激励对象名单（授予日） 一、激励对象名单及拟授出权益分配情况 注 1：上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 注 2：上述任何一名激励对象通过全部有效的股权激励计划获授的本公司股票均未超过本激励 计划草案公告时公司股本总额的 1%。公司全部有效的激励计划所涉及的标的股票总数累计不超过 本激励计划草案公告时公司股本总额的 10%。激励对象因个人原因自愿放弃获授权益的，由董事会 对授予数量作相应调整。 注 3：预留部分的激励对象由本激励计划经股东会审议通过后 12 个月内确定，经董事会提出、 董事会薪酬与考核委员会发表明确意见、律师事务所发表专业意见并出具法律意见书后，公司在指 定网站按要求及时准确披露当次激励对象相关信息。 本激励计划授予的股票期权在各激励对象间的分配情况如下表所示： 序 号 姓名 国籍 职务 获授的股票期 权数量（份） 占授予股票期 权总数的比例 占公司总 股本比例 一、董事、高级管理人员或外籍人员 1 JIZU JOHN CHENG （程健祖） 美国 董事、执行总 裁 470,000 7.58% 0.09% ...

证券代码：300497 证券简称：富祥药业 江西富祥药业股份有限公司 第一期股票期权激励计划（草案） 江西富祥药业股份有限公司第一期股票期权激励计划（草案） 1 江西富祥药业股份有限公司第一期股票期权激励计划（草案） 声明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2 江西富祥药业股份有限公司第一期股票期权激励计划（草案） 特别提示 一、江西富祥药业股份有限公司（以下简称"公司"）第一期股票期权激励计划 （以下简称"本激励计划"）系依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》等有关法律法 规、规范性文件，以及《公司章程》制订。 生命•阳光•未来 二〇二五年十一月 二、本激励计划采用的激励工具为股票期权。股票来源为公司向激励对象定向 发行的公司A股普通股股票。 三、本激励计划拟向激励对象授予不超过620万份的股票期权，约占本激励计划 草案公告时公司股本总额的1.15%。其中，首次授予 ...